Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on April 13, 2018. The registrant is a Delaware corporation and an emerging growth company. The report discloses a planned presentation of clinical data at the 2018 Annual Meeting of the American Association for Cancer Research (AACR).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure regarding clinical trial data rather than financial performance.
Material Changes
No material financial changes versus a prior period are reported in this document. The primary event is the scheduled dissemination of Phase 1 dose escalation data for the Company's drug candidate, pegzilarginase, in patients with advanced solid tumors.
Guidance, Outlook, and Risks
- Management Commentary: The Company will present a poster (Exhibit 99.1) on April 15, 2018, at the AACR meeting in Chicago, Illinois.
- Unusual Items: The information furnished, including the presentation poster, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
- Availability: The presentation poster will be available on the Company's website under the Events & Presentations section.
Investor Verification Checklist
- Verify the clinical data details in the attached Exhibit 99.1 (Presentation Poster) regarding pegzilarginase.
- Confirm the presentation date and location (April 15, 2018, AACR Annual Meeting, Chicago).
- Note that the clinical data is not incorporated by reference into other filings unless expressly stated.
- Check the Company's website (www.aegleabio.com) for the posted presentation materials.